Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 21, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics announced discontinuation of NTLA-3001 program and 27% workforce reduction, triggering potential legal action and stock price decline.
The lawsuit and corporate restructuring directly impact Intellia's stock, signaling potential financial and operational challenges that could negatively affect investor sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100